Jeffery Taylor, MD
Ophthalmology · Paducah, KYNPI 1356318547
Payments from drug & device makers
Across 466 payments — averaging $293.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$87K
- Rxsight Inc$20K
- Novo Nordisk AS$13K
- AbbVie$10K
- Alcon$2K
- Genentech USA, Inc.$631
- plus $4K from 27 others
Across 4 payments — averaging $574.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$2K
What the payments were for
- Consulting fees$10,00055%
- Food & beverage$7,80343%
- Education$2291%
- Other$1401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 114 | $87,291 |
| Rxsight Inc | 13 | $20,320 |
| Novo Nordisk AS | 3 | $13,400 |
| AbbVie(2 entities) | 101 | $9,705 |
| Alcon | 58 | $1,640 |
| Genentech USA, Inc. | 25 | $631 |
| Sight Sciences, Inc. | 17 | $407 |
| Ocular Therapeutix, Inc. | 10 | $346 |
| Regeneron Healthcare Solutions, Inc. | 17 | $329 |
| Bausch & Lomb Americas Inc. | 9 | $257 |
| Oyster Point Pharma, Inc. | 9 | $247 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $241 |
| Apellis Pharmaceuticals, Inc. | 6 | $231 |
| Novartis | 11 | $228 |
| Mallinckrodt Hospital Products Inc. | 4 | $182 |
| Aerie Pharmaceuticals, Inc. | 11 | $156 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $154 |
| Sun Pharmaceutical Industries Inc. | 10 | $146 |
| Shire North American Group Inc | 1 | $125 |
| Dompe US, Inc. | 4 | $116 |
| Amgen(2 entities) | 5 | $96 |
| Tarsus Pharmaceuticals, Inc. | 3 | $82 |
| Biogen | 4 | $81 |
| NEW World Medical,inc. | 4 | $65 |
| Coherus Oncology, Inc. | 3 | $63 |
| Rayner Intraocular Lenses Limited | 2 | $53 |
| Alimera Sciences, Inc. | 2 | $42 |
| Biotissue Holdings Inc. | 4 | $25 |
| Astellas Pharma US Inc | 1 | $20 |
| Harrow Eye, LLC | 1 | $19 |
| Lombart Brothers, Inc. | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $12 |
| Quidel Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$10,127
- Clareon$483
- Tecnis IOL$245
- VABYSMO$145
- XIIDRA$125
- DEXTENZA$125
- Syfovre$123
- Tecnis Simplicity$122
- TYRVAYA$103
- VYZULTA$103
- LOTEMAX SM$101
How this compares
$136,736 in reported general payments places this provider in the 95th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 297 | $151,142 |
| XiidraLifitegrast | 40 | $65,429 |
| RestasisCyclosporine | 41 | $49,917 |
| RhopressaNetarsudil Mesylate | 111 | $48,549 |
| RocklatanNetarsudil Mesylat/Latanoprost | 31 | $18,915 |
| CombiganBrimonidine Tartrate/Timolol | 47 | $17,514 |
| MieboPerfluorohexyloctane/Pf | 19 | $15,516 |
| Travoprost | 40 | $14,770 |
| Brimonidine Tartrate | 284 | $13,551 |
| Latanoprost | 1,207 | $13,069 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 541 | $10,003 |
| ProlensaBromfenac Sodium | 29 | $9,586 |
| Alphagan PBrimonidine Tartrate | 30 | $9,122 |
| TyrvayaVarenicline Tartrate | 11 | $8,341 |
| VyzultaLatanoprostene Bunod | 13 | $7,505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $9,705 | $227,696415 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $257 | $88,45072 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $156 | $67,464142 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $241 | $11,60348 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $247 | $8,34111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in Paducah
- Barbara BowersPaducah$9K
- Brian BodnarchukPaducah$6K
- Landen MeeksPaducah$6K
- Edward HollandEdgewood$1.4M
- Guruprasad PattarLouisville$934K
- Brennan GreeneLouisville$688K
- Johnathon DowningBowling Green$649K
- John MeyerLouisville$587K
- Mohammad HaiderLouisville$498K
- Gary WortzLexington$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.